COVİD-19 ve kanser yönetimi
Yükleniyor...
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Dicle Üniversitesi Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Coronavirüs hastalığı 2019 (COVID-19) şiddetli akut solunum sendromu coronavirüs 2'nin (SARS-CoV-2) neden olduğu
bulaşıcı bir hastalıktır. Dünya Sağlık Örgütü (DSÖ) Mart 2020’de COVID-19 salgınını küresel bir salgın olarak ilan etmiştir.
Kanser hastalığının kendisi ve kanser tedavisinde kullanılan yöntem ve tedavilerin immünsupresyona neden
olabilmelerinden dolayı bu hastalarda COVİD-19 hastalığına yakalanma riski artmaktadır. Ayrıca kanser hastalarında
normal popülasyona göre COVİD-19’a bağlı mortalite oranları daha yüksektir. COVİD-19 pandemisi sürecinde birçok
ülkenin sağlık sisteminde problemler baş göstermiş ve bu problemlerden dolayı çoğu alanda değişiklikler yapılma yoluna
gidilmiştir. Bu bağlamda günlük onkolojik pratikte de değişik modifikasyonlar yapılmış, mevcut koşullara adaptasyon
sağlanmaya çalışılmıştır. Rutin kanser taramaları geçici olarak durdurulmuş, rutin takiplerde bazı koşullarda takip
aralıkları uzatılmıştır. Sağlık sistemlerindeki yüklenmelerden dolayı tanı aşamasında bazı farklılıklar yaşanmıştır.
COVİD-19 pandemi sürecinde immünoterapi, hedefe yönelik ilaçlar ve hormonal ilaçlar COVİD-19 bulaş ve mortalite
riskini arttırmadığından bu ilaçların kullanımı ile ilgili standart yaklaşımda belirgin bir farklılık görülmemektedir.
Bununla birlikte hastane vizitlerini azaltma amacıyla immünoterapi kür aralıklarının uzatılabileceği önerilmiştir.
Kemoterapi alan hastalarda immünsupresyon oluşturma ve enfeksiyon riski nedeni ile uluslararası kılavuzlar
çerçevesinde bazı değişikliklere gidilmiştir. Küratif yaklaşımlarda ve kemoterapiye iyi yanıt alınabilecek tümörlerin
tedavisinde standart yaklaşım önerilirken, metastatik evre palyatif tedavi alan ve kemoterapi etkinliği belirgin olmayan
hastalarda hastayla birlikte tedaviye karar verilmesi önerilmiştir. Sağlık otoriteleri aşılama programlarında kanser tanılı
hastalara öncelik tanımış, aşının kanser hastalarında COVİD-19 bulaşını önleme ve COVİD-19’a bağlı mortaliteyi
azaltmada etkili olduğu gözlenmiştir.
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared the COVID-19 outbreak a global epidemic in March 2020. Cancer disease and the methods and treatments used in cancer treatment can cause immunosuppression. Therefore, the risk of transmission of COVID-19 disease increases in patients with cancer. In addition, mortality rates due to COVID-19 are higher in cancer patients than in the normal population. During the COVID-19 pandemic, problems have arisen in the health systems of many countries, and due to these problems, changes have been made in many areas. In this context, various modifications have been made in daily oncological practice, and adaptation to current conditions has been tried to be achieved. Routine cancer screenings were temporarily stopped, and the follow-up intervals were extended in some conditions during routine follow-ups. There were also differences in the diagnosis process due to the congestion in the health systems. Since immunotherapy, targeted drugs and hormonal drugs do not increase the risk of transmission and mortality during the COVID-19 pandemic, there is no significant difference from the standard approach to the use of these drugs. However, it has been suggested that immunotherapy treatment intervals can be extended in order to reduce hospital visits. Due to the risk of immunosuppression and infection in patients receiving chemotherapy, some changes have been made within the framework of international guidelines. A standard approach is recommended in curative approaches and in the treatment of tumors that can respond well to chemotherapy. However, in cases with no significant chemotherapy efficacy and metastatic stage disease, it is recommended that treatment be decided together with patients. Health authorities gave priority to patients diagnosed with cancer in their vaccination programs, and it was observed that the vaccine was effective in preventing the transmission of COVID-19 in cancer patients and reducing mortality due to COVID-19.
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared the COVID-19 outbreak a global epidemic in March 2020. Cancer disease and the methods and treatments used in cancer treatment can cause immunosuppression. Therefore, the risk of transmission of COVID-19 disease increases in patients with cancer. In addition, mortality rates due to COVID-19 are higher in cancer patients than in the normal population. During the COVID-19 pandemic, problems have arisen in the health systems of many countries, and due to these problems, changes have been made in many areas. In this context, various modifications have been made in daily oncological practice, and adaptation to current conditions has been tried to be achieved. Routine cancer screenings were temporarily stopped, and the follow-up intervals were extended in some conditions during routine follow-ups. There were also differences in the diagnosis process due to the congestion in the health systems. Since immunotherapy, targeted drugs and hormonal drugs do not increase the risk of transmission and mortality during the COVID-19 pandemic, there is no significant difference from the standard approach to the use of these drugs. However, it has been suggested that immunotherapy treatment intervals can be extended in order to reduce hospital visits. Due to the risk of immunosuppression and infection in patients receiving chemotherapy, some changes have been made within the framework of international guidelines. A standard approach is recommended in curative approaches and in the treatment of tumors that can respond well to chemotherapy. However, in cases with no significant chemotherapy efficacy and metastatic stage disease, it is recommended that treatment be decided together with patients. Health authorities gave priority to patients diagnosed with cancer in their vaccination programs, and it was observed that the vaccine was effective in preventing the transmission of COVID-19 in cancer patients and reducing mortality due to COVID-19.
Açıklama
Anahtar Kelimeler
Kanser, COVİD-19, Pandemi, Cancer, COVID-19, Pandemic
Kaynak
Dicle Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
48
Sayı
Özel sayı
Künye
Urakçı, Z., Kalkan, Z. ve Ebinç, S. (2021). COVİD-19 ve kanser yönetimi. Dicle Tıp Dergisi, 48(Özel sayı), 55-64.
